MedTrace Logo

Quality of Recovery After Reversal With Neostigmine or Sugammadex.

NCT02909439 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-05-22

Study results available
· View outcomes & findings →

Summary

This study will compare patient recovery measures after reversal of neuromuscular blockade with neostigmine or sugammadex after surgery. Measures include pulmonary function, muscle strength, time to extubation and quality of recovery in the post anesthesia care unit.

Conditions

  • Incomplete Reversal of Neuromuscular Block

Interventions

DRUG

Sugammadex

Sugammadex will be given for reversal of neuromuscular blockade.

DRUG

Neostigmine

Neostigmine will be given for reversal of neuromuscular blockade.

Sponsors & Collaborators

Principal Investigators

  • Ramon Abola, MD · Stony Brook Medicine, Department of Anesthesiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-11-09
Completion
2018-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02909439 on ClinicalTrials.gov